Ashwin Balagopal, MD

• Chair, ACTG 5335s
• Investigator ACTG 5329 and ACTG 5334s
• Investigator, Hepatitis Transformative Science Group (Feb 2016)

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Johns Hopkins University Baltimore-India Clinical Trials Unit